imagine completed, page-8

Regardless of initial reaction to the start of ASX after some very good days, ADDF’s Executive Director Howard Fillit, MDs statements hit the ball the ball out of the park for me.

“At the time of initiating the trial, we noted that PBT2 stood out as one of the few remaining
orally available agents with clinical trial evidence of cognitive benefit for Alzheimer’s
patients,” Dr Fillit said.

“Since then the relevance of this trial and its design has only increased, in light of the
changing competitive and regulatory landscape for Alzheimer’s drugs in development.”

“The ADDF is proud to have supported this PBT2 trial design that reflects the US Food and
Drug Administration’s new guidelines encouraging companies to look at treating patients
earlier in the disease process.”